Pestalozzi and Ropes & Gray advised Johnson & Johnson on a USD 500 million R&D co-funding agreement with Royalty Pharma to advance the development of JNJ-4804, an investigational co-antibody therapy targeting autoimmune diseases.
Tags :Ropes & Gray
The sale process was initiated by Bridgepoint in early November 2019 but was delayed due to Covid-19 pandemic. Partners Group's general counsel Andreas Knecht (pictured) worked in this transaction.
According to Mergermarket’s Leauge Tables, in the first quarter of 2020, Bär & Karrer is the first Swiss law firm per number of deals. Looking at the tables by value, Lenz & Stahelin tops the ranking.
The software investor Insight Partners has agreed to acquire the Swiss cloud data management Veeam
